Non-pegylated liposomal doxorubicin and docetaxel in metastatic breast cancer: Final results of a phase II trial

Cancer Chemotherapy and Pharmacology

Volumn 64, Issue 2, 2009, Pages 401-406

  Schmid, Peter ^a   Krocker, J ^b   Kreienberg, R ^c   Klare, P ^d   Kittel, K ^d   Sommer, H ^e   Heinrich, G ^d   Steck, T ^f   Lichtenegger, W ^g   Elling, D ^b   Kummel S ^h  

^a CHARING CROSS HOSPITAL   (United Kingdom)

^b SANA KLINIKUM OFFENBACH   (Germany)

^c UNIVERSITY OF ULM   (Germany)

^d Clinic for Gynaecological Oncology   (Germany)

^e UNIVERSITY OF MUNICH   (Germany)

^f Hospital Chemnitz   (Germany)

^g CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^h UNIVERSITY HOSPITAL ESSEN   (Germany)

Author keywords

Cardiotoxicity; Chemotherapy; Docetaxel; Metastatic breast cancer; Non pegylated liposomal doxorubicin

Indexed keywords

ANTIEMETIC AGENT; CORTICOSTEROID; DOCETAXEL; DOXORUBICIN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BONE METASTASIS; BREAST CANCER; CANCER GROWTH; CANCER SURVIVAL; CLINICAL TRIAL; CONGENITAL HEART DISEASE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; HAND FOOT SYNDROME; HEART LEFT VENTRICLE EJECTION FRACTION; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CONDUCTION DISTURBANCE; HUMAN; INFECTION; LEUKOPENIA; LIVER METASTASIS; LUNG METASTASIS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NAIL; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SENSORY NEUROPATHY; SIDE EFFECT; SKIN MANIFESTATION; SOFT TISSUE METASTASIS; STOMATITIS; THROMBOCYTOPENIA; TREATMENT RESPONSE; VISCERAL METASTASIS; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; BREAST NEOPLASMS; DOXORUBICIN; FEMALE; HUMANS; LIVER NEOPLASMS; LUNG NEOPLASMS; MIDDLE AGED; NEOPLASM STAGING; POLYETHYLENE GLYCOLS; PROGNOSIS; SAFETY; SOFT TISSUE NEOPLASMS; SURVIVAL RATE; TAXOIDS; TREATMENT OUTCOME;

EID: 67349168485     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-008-0887-3     Document Type: Article

References (24)

1. GW Sledge D Neuberg P Bernardo 2003 Phase III trial of doxorubicin, paclitaxel, and the combination of doxorubicin and paclitaxel as front-line chemotherapy for metastatic breast cancer: an intergroup trial (E1193) J Clin Oncol 21 588 592 (Pubitemid 46621890)
2. S Chan K Friedrichs D Noel 1999 Prospective randomized trial of docetaxel versus doxorubicin in patients with metastatic breast cancer: the 303 study group J Clin Oncol 17 2341 2354 (Pubitemid 29368232)
3. JM Nabholtz HJ Senn WR Bezwoda 1999 Prospective randomized trial of docetaxel versus mitomycin C plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy J Clin Oncol 17 1413 1424 (Pubitemid 29220847)
4. R Paridaens L Biganzoli P Bruning 2000 Paclitaxel versus doxorubicin as first-line single-agent chemotherapy for metastatic breast cancer: a European Organization for Research and Treatment of Cancer Randomized Study with cross-over J Clin Oncol 18 724 733 (Pubitemid 30106602)
5. J O'Shaughnessy D Miles S Vukelja 2002 Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results J Clin Oncol 20 2812 2823 (Pubitemid 34651510)
6. J-M Nabholtz C Falkson D Campos J Szanto M Martin S Chan T Pienkowski J Zaluski T Pinter M Krzakowski D Vorobiof R Leonard I Kennedy N Azli M Murawsky A Riva P Pouillart 2003 Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial J Clin Oncol 21 6 968 975 (Pubitemid 46594123)
7. Luck HJ, Thomssen C, Untch M et al (2000) Multicentric phase III study in firstline treatment of advanced metastatic breast cancer (ABC). Epirubicin/Paclitaxel (ET) vs Epirubicin/Cyclophosphamide (EC). A study of the Ago Breast Cancer Group. ASCO Online (American Society of Clinical Oncology). American Society of Clinical Oncology (abstract 280)
8. J Bonneterre V Dieras M Tubiana-Hulin P Bougnoux M Bonneterre T Delozier S Culine N Dohollou J Suissa R Samak 2004 Phase II multicentre randomised study of docetaxel plus epirubicin vs 5-fluorouracil plus epirubicin and cyclophosphamide in metastatic breast cancer Br J Cancer 91 8 1466 1471 (Pubitemid 39486349)
9. M Bontenbal JJ Braun GJ Creemers 2005 Phase II to III study comparing doxorubicin and docetaxel with fluorouracil, doxorubicin, and cyclophosphamide as first-line chemotherapy in patients with metastatic breast cancer: results of a Dutch Community Setting Trial for the Clinical Trial Group of the Comprehensive Cancer Centre J Clin Oncol 23 28 7081 7088 (Pubitemid 46260296)
10. L Biganzoli T Cufer P Bruning R Coleman L Duchateau AH Calvert T Gamucci C Twelves P Fargeat R Epelbaum C Lohrisch MJ Piccart 2002 Doxorubicin and paclitaxel versus doxorubicin and cyclophosphamide as first-line chemotherapy in metastatic breast cancer: EORTC 10961 J Clin Oncol 20 14 3114 3121
11. J Jassem T Pienkowski A Pluzanska S Jelic V Gorbunova Z Mrsic-Krmpotic J Berzins T Nagykalnai N Wigler J Renard S Munier C Weil 2001 Central. Doxorubicin and paclitaxel versus fluorouracil, doxorubicin, and cyclophosphamide as first-line therapy for women with metastatic breast cancer: final results of a randomized phase III multicenter trial J Clin Oncol 19 6 1707 1715 (Pubitemid 32230871)
12. K Shan AM Lincoff JB Young 1996 Anthracycline-induced cardiotoxicity Ann Intern Med 125 1 47 58
13. DD Von Hoff MW Layard P Basa 1979 Risk factors for doxorubicin-induced congestive heart failure Ann Intern Med 91 5 710 717 (Pubitemid 10218041)
14. SM Swain FS Whaley MS Ewer 2003 Congestive heart failure in patients treated with doxorubicin Cancer 97 11 2869 2879
15. A Cabanes D Tzemach D Goren AT Horowitz A Gabizon 1998 Comparative study of the antitumor activity of free doxorubicin and polyethylene glycol-coated liposomal doxorubicin in a mouse lymphoma model Clin Cancer Res 4 2 499 505 (Pubitemid 28122769)
16. A Gabizon R Catane B Uziely 1994 Prolonged circulation time and enhanced accumulation in malignant exudates of doxorubicin encapsulated in polyethylene-glycol coated liposomes Cancer Res 54 4 987 992 (Pubitemid 24085451)
17. FJ Martin 1997 Pegylated liposomal dixirubicin: Scientific rationale and prelinical pharmacology Oncology 11 suppl 11 11 20
18. S Stewart KJ Harrington 1997 The biodistribution and pharmacokinetics of stealth liposomes in patients with solid tumors Oncology 11 suppl 11 33 37
19. L Harris G Batist R Belt D Rovira R Navari N Azarnia L Welles E Winer TLC D-99 Study Group 2002 Liposome-encapsulated doxorubicin compared with conventional doxorubicin in a randomized multicenter trial as first-line therapy of metastatic breast carcinoma Cancer 94 1 25 36 (Pubitemid 34049039)
20. G Batist G Ramakrishnan C Sekhar Rao A Chandrasekharan J Gutheil T Guthrie P Shah A Khojasteh M Krishnan Nair K Hoelzer K Tkaczuk Y Choi Park LW Lee 2001 Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide in a randomized, multicenter trial of metastatic breast cancer J Clin Oncol 19 1444 1454 (Pubitemid 32202552)
21. S Chan N Davidson E Juozaityte F Erdkamp A Pluzanska N Azarnia LW Lee 2004 Phase III trial of liposomal doxorubicin and cyclophosphamide compared with epirubicin and cyclophosphamide as first-line therapy for metastatic breast cancer Ann Oncol 15 10 1527 1534 (Pubitemid 39409744)
22. AM Keller RG Mennel VA Georgoulias JM Nabholtz A Erazo A Lluch CL Vogel M Kaufmann G von Minckwitz IC Henderson L Mellars L Alland C Tenlder 2004 Randomized phase III trial of pegylated liposomal doxorubicin versus vinorelbine or mitomycin C plus vinblastine in women with taxane-refractory advanced breast cancer J Clin Oncol 22 19 3893 3901 (Pubitemid 41079870)
23. ME O'Brien N Wigler M Inbar R Rosso E Grischke A Santoro R Catane DG Kieback P Tomczak SP Ackland F Orlandi L Mellars L Alland C Tendler CAELYX Breast Cancer Study Group 2004 Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer Ann Oncol 15 3 440 449 (Pubitemid 38444547)
24. MJ Piccart-Gebhart T Burzykowski M Buyse G Sledge J Carmichael HJ Lück JR Mackey JM Nabholtz R Paridaens L Biganzoli J Jassem M Bontenbal J Bonneterre S Chan GA Basaran P Therasse 2008 Taxanes alone or in combination with anthracyclines as first-line therapy of patients with metastatic breast cancer J Clin Oncol 26 12 1980 1986